Unlocking the Potential of C8orf34: A Protein Target for Cancer Treatment

Target Name: C8orf34

NCBI ID: G116328

C8orf34

Unlocking the Potential of C8orf34: A Protein Target for Cancer Treatment

Introduction

Cancer is one of the leading causes of human mortality, affecting millions of people worldwide. The development of new treatments is crucial for improving the lives of patients. One promising approach to combat cancer is the targeting of specific proteins involved in the disease process. In this article, we focus on C8orf34, a protein that has gained significant attention due to its potential as a drug target or biomarker.

C8orf34: A Protein LINKED TO CANCER

C8orf34, also known as PIK3CA, is a gene mutation-induced protein that plays a critical role in the development and progression of cancer. The protein is named after the PIK3CA gene, which is located on chromosome 18 near the tumor suppressor gene p53. PIK3CA mutations have been implicated in the development of numerous types of cancer, including breast, ovarian, and colorectal cancer.

C8orf34 functions as a negative regulator of the PI3K/Akt signaling pathway, which is known to play a central role in cancer growth and progression. The PI3K/Akt pathway is a critical pathway involved in cell survival and proliferation, and dysregulation of this pathway has has been implicated in numerous diseases, including cancer.

C8orf34's Role in Cancer Development

C8orf34's involvement in cancer development becomes even more significant when it is mutated or expressed at high levels. Studies have shown that PIK3CA mutations lead to increased activation of the PI3K/Akt signaling pathway, leading to increased cell proliferation and survival. This is because the PI3K /Akt pathway is activated by oncogenes, such as mutations, which increase the activity of the protein kinase Akt.

C8orf34 has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer cells. In addition, high levels of C8orf34 have been observed in various types of cancer, including tumors. This suggests that targeting C8orf34 may be an effective strategy for cancer treatment.

C8orf34 as a Drug Target

C8orf34's potential as a drug target is due to its unique mechanism of action and its involvement in cancer development. C8orf34 functions as a negative regulator of the PI3K/Akt signaling pathway, making it an attractive target for small molecules that can inhibit this pathway.

Several small molecules have been shown to inhibit the activity of C8orf34, including inhibitors of the PI3K/Akt signaling pathway, such as tyrrocambaline, a drug used in the treatment of Parathyroidism. Tyrrocambaline has been shown to inhibit the activity of C8orf34 and reduce the growth of cancer cells.

C8orf34 also has been shown to interact with several protein partners, including PTEN, a protein that has been implicated in the development of many types of cancer. The interaction between C8orf34 and PTEN suggests that targeting C8orf34 may be an effective strategy for cancer treatment.

C8orf34 as a Biomarker

C8orf34 is also an attractive biomarker for cancer, as its levels are often elevated in cancer cells. This suggests that measuring the levels of C8orf34 may be an effective way to monitor the effectiveness of cancer treatments.

C8orf34 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that C8orf34 levels are often elevated in cancer tissues, which suggests that it may be an effective biomarker for cancer diagnosis and treatment.

Conclusion

C8orf34 is a protein that has gained significant attention due to its potential as a drug target or biomarker

Protein Name: Chromosome 8 Open Reading Frame 34

The "C8orf34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C8orf34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets